ATMP GMP (Part IV)

Regulation (EC) 1394/2007 defines four ATMP categories: gene therapy medicinal products (recombinant nucleic acid in or administered to humans for therapeutic, prophylactic or diagnostic purposes), somatic cell therapy medicinal products (cells/tissues substantially manipulated or used for a non-homologous function), tissue-engineered products (cells/tissues with cells/tissues engineered as part of the product), and combined ATMPs (one of the above incorporating a medical device).

ATMPs include CAR-T cell therapies, gene-editing products, AAV-delivered gene replacement, autologous chondrocyte implants, dendritic-cell vaccines, ex vivo modified haematopoietic stem cells and similar advanced modalities.

Standard EU GMP was written for large-scale chemical and biological manufacture: long shelf life, batch sizes in the kilograms or millions of units, robust analytical and release windows, controlled supply chains. ATMPs frequently invert every one of those: batch size of one (autologous), shelf life of hours to days, starting materials sourced from individual patients with variable biology, mandatory release before all conventional testing has completed (sterility test alone takes 14 days).

Part IV adapts the GMP framework to this reality: risk-based application of controls proportionate to the actual risk to the patient; explicit accommodation of short shelf life via parametric or rapid microbiological methods; tightly controlled chain of identity and chain of custody from patient to patient; permitted use of in-process and surrogate testing when conventional release testing cannot complete in time.

Part IV explicitly endorses a risk-based approach to GMP application. The depth and rigour of each control is sized to the actual risk to product quality and patient safety. A small autologous cell-therapy operation does not need to apply the same controls a large allogeneic AAV manufacturing facility applies; both apply GMP, but the implementation differs.

The risk-based decisions are documented and justified in the Pharmaceutical Quality System. ICH Q9(R1) is the methodology of choice. Risk-based does not mean reduced — it means proportionate, and it requires positive justification for every relaxation of a default expectation.

For autologous and donor-specific products, the chain of identity from patient/donor to administered dose must be unbroken. Part IV requires unique identifiers persisting from collection through manufacturing through return to the patient, reconciliation at every step, and verification at administration. Chain of custody — the physical/legal control of the material — is documented in parallel.

Mix-ups in autologous manufacturing are catastrophic (a patient receives another patient's modified cells) and chain-of-identity controls are correspondingly stringent: double-identifier checks, segregated processing where possible, electronic verification at each handoff, reconciliation at the end of each major step.

Many ATMPs have shelf lives measured in hours (fresh autologous CAR-T can be 72 hours from end-of-manufacture to administration). Conventional sterility testing (14-day USP <71> / Ph. Eur. 2.6.1) cannot complete in that window. Part IV accommodates this via rapid microbiological methods (BacT/ALERT, BACTEC), endotoxin testing by LAL, mycoplasma testing by NAT-based methods, and conditional release pending the conventional sterility result.

When conditional release is used, the responsibility of the QP includes a defined procedure for action if the conventional sterility test fails post-administration — notification of the treating physician, patient monitoring and any necessary intervention. The conditional release framework is documented in the marketing authorisation.

ATMP starting materials are frequently primary human cells or tissues collected at clinical sites under specific consent and quality controls (apheresis, biopsy, bone-marrow aspirate). The GMP boundary is the moment of receipt at the manufacturing site, but the manufacturer must ensure the collection complies with relevant tissue-and-cell directives (2004/23/EC, 2006/17/EC, 2006/86/EC) and is performed under documented quality conditions.

Critical raw materials (viral vectors, cytokines, culture media, plasmids) often have limited regulatory pedigree because they are research-grade or single-source. Part IV requires qualification proportional to the criticality and the manufacturer's risk-based assessment.

Part IV permits flexible facility design: closed processing systems can dispense with the air-quality classification of the surrounding environment; multi-product facilities can be justified with adequate segregation and changeover controls; small-scale autologous suites can use single-use systems with minimal hard infrastructure. The 2022 Annex 1 sterile-product expectations apply where the product reaches an aseptic step in open processing.

Annex 2A (Manufacture of Advanced Therapy Medicinal Products for Human Use) was finalised in 2023 as an additional aid to interpretation, particularly on the interfaces between Part IV and Annex 1 (sterile manufacture) for ATMPs. It does not replace Part IV; it complements it. Operators should read both, with Part IV as the primary document for the GMP framework and Annex 2A as additional guidance on sterile-processing alignment.

• Misinterpreting 'risk-based' as 'less rigorous' rather than 'proportionate and justified'.
• Chain-of-identity breaks at the collection-site interface — the GMP boundary is the manufacturing site but the patient-identity integrity starts at collection.
• Conditional release without a robust post-result procedure for sterility failures.
• Inadequate qualification of single-source critical raw materials (viral vectors in particular).
• Facility design that assumes Annex 1 grade-A surrounded by grade-B by default, when a closed system would permit lower-grade backgrounds.